Why a non-invasive prenatal test?
Non-invasive prenatal tests can prevent the need for about 98% of invasive tests in patients at risk for T211.
* The current standard for detecting prenatal chromosomal alterations requires
the use of invasive techniques (amniocentesis and chorionic villus biopsy), which carry a risk between 0.5%-2% of spontaneous abortion.
* NACE® provides reliable information which avoids the need for unnecessary invasive techniques.
According to data from the 2012 European Registry for Prenatal Diagnosis2, abnormalities
in chromosomes 21, 18, and 13 represent 71% of all chromosomal alterations detected.
Detection rate according to the type of screening
1. Chui et al., BMJ 2011;342:c7401.
2. Dan S., et al. Clinical application of MPS-based prenatal non invasive fetal trisomy test for trisomias 21 and 18 in 1110S pregnancies with mixed risk factors.
3. DasChakraborty R, Bernal AJ, Schoch K, Howard TD, Ip EH, et al. (2012) Dysregulation of DGCR6 and DGCR6L: psychopathological outcomes in chromosome 22q11.2 deletion syndrome. Transl Psychiatry. 2: e105. doi:10.1038/tp.2012.31.
* Includes maternal age, nuchal translucency measurement, and the detection of the PAPP-A and free B-HCG biochemical markers.
** Includes other ultrasound markers: nasal bone absence, assessment of the ductus venosus, and tricuspid blood flow. (FP = false positives).